Back
Articles
08/28/2024

Advances in minimal residual disease monitoring in multiple myeloma - Clinical Laboratory Sciences 2023

Wijnands, C., Noori, S., Donk, N. W. C. J. van de, VanDuijn, M. M., & Jacobs, J. F. M.

Critical Reviews in Clinical Laboratory Sciences, 60(7), 518–534. (2023) https://doi.org/10.1080/10408363.2023.2209652
decoration

Advances in minimal residual disease monitoring in multiple myeloma

This review provides an overview of state-of-the-art of MRD monitoring, describes new developments and applications of blood-based MRD monitoring, and suggests future directions for its successful integration into the clinical management of MM patients.

Access the Critical Review

Access

More articles

View all articles
Articles
08/22/2024

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients - CCLM 2024

Articles
06/29/2023

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020

Articles
08/28/2023

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020

Articles
06/29/2023

Extramedullary disease in multiple myeloma: a systematic literature review - Blood Cancer J. 2022

Articles
06/29/2023

IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016

Articles
08/22/2024

M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator - CCLM 2024

Articles
06/29/2023

Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021

Articles
06/08/2023

Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders - Blood Cancer J. 2021

Articles
06/29/2023

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022

Articles
06/29/2023

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021

Articles
06/29/2023

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! - Journal of Clinical Oncology, 2022

Articles
08/28/2023

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021